MILWAUKEE, Sept. 26, 2023 /PRNewswire/ -- Ademi LLP is investigating Intercept ICPT for possible breaches of fiduciary duty and other violations of law in its transaction with Alfasigma.
Click here to learn how to join the action https://www.ademilaw.com/case/intercept-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Intercept stockholders are expected to receive only $19 per share in cash. The transaction agreement unreasonably limits competing transactions for Intercept by imposing a significant penalty if Intercept accepts a competing bid. Intercept insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Intercept's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Intercept common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/intercept-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
